Medeze Addresses Concerns Over Stem Cell Use in Clarification to Thai Stock Exchange.

Bangkok: MEDEZE issues a clarification letter to the Stock Exchange of Thailand after the Medical Council expressed concerns about the use of stem cells. MEDEZE sent a letter of explanation to the Stock Exchange of Thailand after the Medical Council expressed concern and wanted to promote the widespread use of stem cells correctly, confirming that the storage system meets the standards and is used in accordance with the announcement of the Ministry of Public Health. According to Thai News Agency, Dr. Veerapol Khemarangsan, Chief Executive Officer of Medeze Group Public Company Limited (MEDEZE), wrote a letter to the Director and Manager of the Stock Exchange of Thailand (SET). The letter addressed concerns raised by online and other media that could potentially worry shareholders and investors about the company's operations. These concerns arose from an academic seminar, 'Chuan Mor Ru' episode 5, held on October 31, 2024, discussing the use of stem cells for disease treatment. The seminar was jointly organiz ed by the Ministry of Public Health, the Medical Council, the Department of Health Service Support, and the Food and Drug Administration, where the Medical Council emphasized the correct use of stem cells. The company clarified that it serves solely as a stem cell banking service provider, adhering to international frozen storage standards set by the Association for Advancement of Blood and Biotherapies (AABB) in the United States. These standards are in compliance with quality control standards specified by the US Food and Drug Administration (USFDA). MEDEZE is not a hospital and ensures that its stem cell storage services, including examination, separation, and cultivation, meet medical standards as well as cell bank standards in Thailand. Stem cell treatments are administered only by the person who owns the stored stem cells and are conducted under the supervision of a physician and hospital, complying with legal regulations and standards set by the Ministry of Public Health. Additionally, the Company em phasized its commitment to responsible advertising and public relations. It has established advertising standards and a control policy based on the Hospital Act. A risk management working group, comprising executives and employees, collaborates to oversee advertising and public relations, reporting to the Board of Directors to prevent legal violations, including future legislative changes. MEDEZE urged shareholders, investors, and relevant parties to trust in the company's adherence to legal, regulatory, and ethical standards. The company reiterated its dedication to good governance, transparency, and accountability while continuing to provide stem cell storage services and developing innovations for the legal use of stem cells.